144 related articles for article (PubMed ID: 30753829)
1. Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer.
Hellmann MD; Callahan MK; Awad MM; Calvo E; Ascierto PA; Atmaca A; Rizvi NA; Hirsch FR; Selvaggi G; Szustakowski JD; Sasson A; Golhar R; Vitazka P; Chang H; Geese WJ; Antonia SJ
Cancer Cell; 2019 Feb; 35(2):329. PubMed ID: 30753829
[No Abstract] [Full Text] [Related]
2. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials.
D'Angelo SP; Mahoney MR; Van Tine BA; Atkins J; Milhem MM; Jahagirdar BN; Antonescu CR; Horvath E; Tap WD; Schwartz GK; Streicher H
Lancet Oncol; 2018 Mar; 19(3):416-426. PubMed ID: 29370992
[TBL] [Abstract][Full Text] [Related]
3. Nivolumab versus ipilimumab in the treatment of advanced melanoma: a critical appraisal: ORIGINAL ARTICLE: Wolchok JD, Chiarion-Sileni V, Gonzalez R et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 2017; 377:1345-56.
Wan MT; Ming ME
Br J Dermatol; 2018 Aug; 179(2):296-300. PubMed ID: 29766492
[TBL] [Abstract][Full Text] [Related]
4. Role of Immune Checkpoint Inhibitors in Small Cell Lung Cancer.
Cooper MR; Alrajhi AM; Durand CR
Am J Ther; 2018; 25(3):e349-e356. PubMed ID: 29722737
[TBL] [Abstract][Full Text] [Related]
5. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study.
Long GV; Atkinson V; Lo S; Sandhu S; Guminski AD; Brown MP; Wilmott JS; Edwards J; Gonzalez M; Scolyer RA; Menzies AM; McArthur GA
Lancet Oncol; 2018 May; 19(5):672-681. PubMed ID: 29602646
[TBL] [Abstract][Full Text] [Related]
6. Nivolumab monotherapy or in combination with ipilimumab for metastatic melanoma: systematic review and meta-analysis of randomized-controlled trials.
Menshawy A; Eltonob AA; Barkat SA; Ghanem A; Mniesy MM; Mohamed I; Abdel-Maboud M; Mattar OM; Elfil M; Bahbah EI; Elgebaly A
Melanoma Res; 2018 Oct; 28(5):371-379. PubMed ID: 29957656
[TBL] [Abstract][Full Text] [Related]
7. Combination immune checkpoint blockade with ipilimumab and nivolumab in the management of advanced melanoma.
Spain L; Larkin J
Expert Opin Biol Ther; 2016; 16(3):389-96. PubMed ID: 26750801
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma.
Blank CU; Rozeman EA; Fanchi LF; Sikorska K; van de Wiel B; Kvistborg P; Krijgsman O; van den Braber M; Philips D; Broeks A; van Thienen JV; Mallo HA; Adriaansz S; Ter Meulen S; Pronk LM; Grijpink-Ongering LG; Bruining A; Gittelman RM; Warren S; van Tinteren H; Peeper DS; Haanen JBAG; van Akkooi ACJ; Schumacher TN
Nat Med; 2018 Nov; 24(11):1655-1661. PubMed ID: 30297911
[TBL] [Abstract][Full Text] [Related]
9. Nivolumab: A Review in Advanced Melanoma.
Scott LJ
Drugs; 2015 Aug; 75(12):1413-24. PubMed ID: 26220912
[TBL] [Abstract][Full Text] [Related]
10. Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma.
Rosner S; Kwong E; Shoushtari AN; Friedman CF; Betof AS; Brady MS; Coit DG; Callahan MK; Wolchok JD; Chapman PB; Panageas KS; Postow MA
Cancer Med; 2018 Mar; 7(3):690-697. PubMed ID: 29468834
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis.
D'Angelo SP; Larkin J; Sosman JA; Lebbé C; Brady B; Neyns B; Schmidt H; Hassel JC; Hodi FS; Lorigan P; Savage KJ; Miller WH; Mohr P; Marquez-Rodas I; Charles J; Kaatz M; Sznol M; Weber JS; Shoushtari AN; Ruisi M; Jiang J; Wolchok JD
J Clin Oncol; 2017 Jan; 35(2):226-235. PubMed ID: 28056206
[TBL] [Abstract][Full Text] [Related]
12. Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma.
Zimmer L; Apuri S; Eroglu Z; Kottschade LA; Forschner A; Gutzmer R; Schlaak M; Heinzerling L; Krackhardt AM; Loquai C; Markovic SN; Joseph RW; Markey K; Utikal JS; Weishaupt C; Goldinger SM; Sondak VK; Zager JS; Schadendorf D; Khushalani NI
Eur J Cancer; 2017 Apr; 75():47-55. PubMed ID: 28214657
[TBL] [Abstract][Full Text] [Related]
13. Response to the treatment immediately before nivolumab monotherapy may predict clinical response to nivolumab in patients with non-small cell lung cancer.
Kobayashi H; Omori S; Nakashima K; Wakuda K; Ono A; Kenmotsu H; Naito T; Murakami H; Endo M; Takahashi T
Int J Clin Oncol; 2017 Aug; 22(4):690-697. PubMed ID: 28382561
[TBL] [Abstract][Full Text] [Related]
14. Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology.
Barbee MS; Ogunniyi A; Horvat TZ; Dang TO
Ann Pharmacother; 2015 Aug; 49(8):907-37. PubMed ID: 25991832
[TBL] [Abstract][Full Text] [Related]
15. Real-world efficacy and toxicity of combined nivolumab and ipilimumab in patients with metastatic melanoma.
Parakh S; Randhawa M; Nguyen B; Warburton L; Hussain MA; Cebon J; Millward M; Yip D; Ali S
Asia Pac J Clin Oncol; 2019 Feb; 15(1):26-30. PubMed ID: 30426665
[TBL] [Abstract][Full Text] [Related]
16. Nivolumab-ipilimumab - exploiting the mutation burden of NSCLCs.
Killock D
Nat Rev Clin Oncol; 2018 Jul; 15(7):403. PubMed ID: 29703915
[No Abstract] [Full Text] [Related]
17. High TMB Predicts Immunotherapy Benefit.
Cancer Discov; 2018 Jun; 8(6):668. PubMed ID: 29661758
[TBL] [Abstract][Full Text] [Related]
18. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab.
Cappelli LC; Gutierrez AK; Baer AN; Albayda J; Manno RL; Haque U; Lipson EJ; Bleich KB; Shah AA; Naidoo J; Brahmer JR; Le D; Bingham CO
Ann Rheum Dis; 2017 Jan; 76(1):43-50. PubMed ID: 27307501
[TBL] [Abstract][Full Text] [Related]
19. Genomic Features of Response to Combination Immunotherapy in Lung Cancer.
Früh M; Peters S
Cancer Cell; 2018 May; 33(5):791-793. PubMed ID: 29763618
[TBL] [Abstract][Full Text] [Related]
20. Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology.
Selby MJ; Engelhardt JJ; Johnston RJ; Lu LS; Han M; Thudium K; Yao D; Quigley M; Valle J; Wang C; Chen B; Cardarelli PM; Blanset D; Korman AJ
PLoS One; 2016; 11(9):e0161779. PubMed ID: 27610613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]